secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001171843-24-006039
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Q3 net loss $19.7M; imdusiran/AB-101 data upcoming; cash into Q4 2026
-----------------------------------------------------------------------------

- Net loss $19.7M ($0.10 per share) vs $20.1M prior year; revenue fell to $1.3M from $4.7M on lower license and royalty income.
- Cash and investments $130.8M; 2024 cash burn expected $63M-$67M; runway into Q4 2026.
- Imdusiran HBsAg loss data from IM-PROVE I/II to be presented at AASLD Nov 2024; additional follow-up and nivolumab cohort data.
- AB-101 oral PD-L1 inhibitor advanced to Part 3 in cHBV patients; preliminary data expected H1 2025.
- LNP litigation vs Moderna trial set Sept 2025; Pfizer claim construction Dec 18, 2024; restructuring charge $3.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324006039/0001171843-24-006039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324006039/f8k_110624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer